TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05110196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib 150 mg
Description: Capmatinib film-coated tablet 150 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib 200 mg
Description: Capmatinib film-coated tablet 200 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
Study: NCT06585969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Description: Trastuzumab deruxtexan every three weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribociclib with ET
Description: Ribociclib with endocrine therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib with ET
Description: Abemaciclib with endocrine therapy
Study: NCT06656299

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided external oblique intercostal plane block
Description: ultrasound guided external oblique intercostal plane block

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine injection
Description: 5 ml local anesthetic for each trocar sides

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol, tramadol, and ondansetron
Description: As standard multimodal analgesia, 20 min before the end of the surgery patients will receive 1 g of paracetamol, 1-2 mg/kg of tramadol, and 4 mg of ondansetron via intravenous infusion.~All patients will be recovered in the PACU, and after confirming an Aldrete score of \>9, a PCA (patient-controlled analgesia) device will be installed with morphine prepared at a dose appropriate for the patient's age. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. When patients have a Numerical Rating Scale (NRS) score is ≥ 4, 1 mg/kg iv tramadol will be administered as a rescue analgesic

Intervention type: DRUG
Group type: OTHER
Intervention: paracetamol, tramadol, and ondansetron
Description: As standard multimodal analgesia, 20 min before the end of the surgery patients will receive 1 g of paracetamol, 1-2 mg/kg of tramadol, and 4 mg of ondansetron via intravenous infusion.~All patients will be recovered in the PACU, and after confirming an Aldrete score of \>9, a PCA (patient-controlled analgesia) device will be installed with morphine prepared at a dose appropriate for the patient's age. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. When patients have a Numerical Rating Scale (NRS) score is ≥ 4, 1 mg/kg iv tramadol will be administered as a rescue analgesic
Study: NCT05602376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: U=U testing messaging scripts
Description: On site testing days randomized to the intervention, trained health promoters employed by the mobile testing venues will use U=U messaging scripts to invite men in the vicinity to seek HIV testing services on that day. On intervention days, the U=U messaging will also be used by counselors at the testing venue when referring those who test HIV positive to clinic-based ART initiation services provided by the local Department of Health

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: U=U adherence messaging scripts
Description: After receiving standard ART initiation and adherence counselling from a DoH clinic nurse per South African National Guidelines, RCs will deliver a U=U message and hand participants a small business card with a brief U=U message on it. Participants will then receive monthly SMS booster messages (but can opt out) and monthly in-clinic booster messages during routine medical refill visits, again with a business card for messaging reinforcement.
Study: NCT06665763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Lactate Solution
Description: Infusion of sodium-lactate solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline infusion (placebo)
Description: NaCl solution
Study: NCT06668064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP-1901
Description: Intravitreal Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept (2.0 mg)
Description: Intravitreal Injection
Study: NCT06669923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSIPsmarter Program
Description: web-based behavioral intervention to reduce sugary drink intake

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Patient Education
Description: website with information about cancer screening and prevention (e.g. screening tests for seven types of cancer)
Study: NCT06669650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PGx guided personalized post-operative pain management
Description: Patients in the intervention group will receive post operative opioid therapy based on their pharmacogenomic results. Patients who are poor CYP2D6 metabolizers or rapid CYP2D6 metabolizers with moderate or severe pain, will be prescribed either oral hydromorphone 2mg every 4 hours as needed or oral hydromorphone 4mg every 4 hours as needed, respectively. Patients who are intermediate or normal CYP2D6 metabolizers with moderate or severe pain will receive oxycodone 5mg or oxycodone 10mg every 4 hours as needed respectively similar to the treatment offered to the control subjects. Normal or intermediate CYP2D6 metabolizers who are concomitantly taking a drug which is a strong CYP2D6 inducer will be treated as if they are in the rapid metabolizer group, and normal or intermediate patients that are concomitantly taking a drug which is a strong CYP2D6 inhibitor will be treated as if they were a poor metabolizer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PGx guided personalized post-operative pain management
Description: Patients in the intervention group will receive post operative opioid therapy based on their pharmacogenomic results. Patients who are poor CYP2D6 metabolizers or rapid CYP2D6 metabolizers with moderate or severe pain, will be prescribed either oral hydromorphone 2mg every 4 hours as needed or oral hydromorphone 4mg every 4 hours as needed, respectively. Patients who are intermediate or normal CYP2D6 metabolizers with moderate or severe pain will receive oxycodone 5mg or oxycodone 10mg every 4 hours as needed respectively similar to the treatment offered to the control subjects. Normal or intermediate CYP2D6 metabolizers who are concomitantly taking a drug which is a strong CYP2D6 inducer will be treated as if they are in the rapid metabolizer group, and normal or intermediate patients that are concomitantly taking a drug which is a strong CYP2D6 inhibitor will be treated as if they were a poor metabolizer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: oxycodone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: hydromorphone
Study: NCT06669546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase-locked auditory stimulation (PLAS)
Description: Intervention: Verum Phase-Locked Auditory Stimulation (PLAS) Using the SleepLoop Device.~The experimental intervention utilizes the SleepLoop device, a home-use, EEG-based system designed for phase-locked acoustic stimulation (PLAS). The device continuously monitors sleep through EEG (Fpz) alongside electrooculogram (EOG) and electromyogram (EMG) channels. The device employs a closed-loop algorithm that detects slow oscillations (SOs) in the EEG and delivers short sound stimuli (50 ms pink noise) during the positive half-waves of slow waves in slow-wave sleep (SWS). These stimuli are delivered through integrated headphones in the SleepLoop device. The intervention is applied during work days for 4 weeks. The algorithm is only active during SWS and does not deliver stimuli when the participant is awake, or in lighter sleep stages (N1, N2) or REM sleep. The intensity and algorithm sensitivity are individually calibrated for each participant to optimize stimulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase-locked auditory stimulation (PLAS)
Description: Intervention: Verum Phase-Locked Auditory Stimulation (PLAS) Using the SleepLoop Device.~The experimental intervention utilizes the SleepLoop device, a home-use, EEG-based system designed for phase-locked acoustic stimulation (PLAS). The device continuously monitors sleep through EEG (Fpz) alongside electrooculogram (EOG) and electromyogram (EMG) channels. The device employs a closed-loop algorithm that detects slow oscillations (SOs) in the EEG and delivers short sound stimuli (50 ms pink noise) during the positive half-waves of slow waves in slow-wave sleep (SWS). These stimuli are delivered through integrated headphones in the SleepLoop device. The intervention is applied during work days for 4 weeks. The algorithm is only active during SWS and does not deliver stimuli when the participant is awake, or in lighter sleep stages (N1, N2) or REM sleep. The intensity and algorithm sensitivity are individually calibrated for each participant to optimize stimulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Phase-Locked Auditory Stimulation
Description: Participants will undergo the same procedure as the real Phase-Locked Auditory Stimulation (PLAS) intervention. However, during the sham condition, the headphones are turned off, and no auditory stimulation is delivered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Phase-Locked Auditory Stimulation
Description: Participants will undergo the same procedure as the real Phase-Locked Auditory Stimulation (PLAS) intervention. However, during the sham condition, the headphones are turned off, and no auditory stimulation is delivered.
Study: NCT06670859

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention-Control:
Description: Patients will complete the STAI before the first mobilization after surgery and then the patients' pain status and the level of anxiety they feel about their physical privacy with the mobilization coverall they will wear during mobilization will be assessed with the VAS.Than,will be asked to perform 4 activities (putting on the coverall-mobilization-sitting in the wheelchair and moving-taking off the coverall) with the overall.Than,will be asked to evaluate the indicator level that they think the coverall they wear protects physical privacy and the levels of comfort and satisfaction they feel about the coverall with the VAS.During the next mobilization,patients will be asked to perform the same application protocol with a traditional hospital gown.Participants who have tried both clothing designs will be interviewed about their experiences using 'interview form' their satisfaction.Than interview,participants will have completed the study by filling out the QUEST 2.0.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control-Intervention
Description: Patients will complete the STAI before the first mobilization after surgery and then the patients' pain status and the level of anxiety they feel about their physical privacy with the traditional hospital gown they will wear during mobilization will be assessed with the VAS.Than,will be asked to perform 4 activities (putting on the gown-mobilization-sitting in the wheelchair and moving-taking off the gown) with the gown.Than,will be asked to evaluate the indicator level that they think the gown they wear protects physical privacy, and the levels of comfort and satisfaction they feel about the gown with the VAS.During the next mobilization, patients will be asked to perform the same application protocol with the mobilization coverall.Participants who have tried both clothing designs will be interviewed about their experiences using 'interview form' their satisfaction.At the end of the interview, participants will have completed the study by filling out the QUEST 2.0.
Study: NCT06670937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induced sputum
Description: Patients will provide 1) an induced sputum sample after inhaling 15 ml of 0.9% NaCl solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Patients will provide 2) a blood sample.
Study: NCT05556525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorescein
Description: Given IV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Image-Guided Needle Confocal Laser Endomicroscopy
Description: Undergo nCLE

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-Guided Transbronchial Needle Aspiration
Description: Undergo EBUS TBNA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Transbronchial Needle Aspiration
Description: Undergo EBUS TBNA
Study: NCT06630455

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meu-cinn
Description: Meu-cinn 250 mg/day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 250 mg/day for 8 weeks
Study: NCT05677087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREPARE Nutrition Education Module
Description: The Perinatal Remote Education for Pandemic Resilience (PREARE) program is a 6-week intensive program aimed at increasing maternal and infant dietary diversity as well as maternal health literacy. Modules that will be completed in the program include education on early initiation of breastfeeding, food groups and the benefits of a balanced diet, appropriate meal frequency for mother and infant, and appropriate sources of health information. Information on personal hygiene and COVID-19 hygiene protocols as well as danger signs during pregnancy are included in the module to improve maternal knowledge on safety protocols and pregnancy complications.
Study: NCT05198765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BMI-CDS
Description: The BMI-CDS is a sophisticated point of care shared decision support tool for patients with type 2 diabetes and high BMI. The intervention is built on existing point of care clinical decision support system that algorithmically identifies study-eligible patients and deploys patient-specific CDS output at an index visit and updated CDS all subsequent primary care office, video, and phone encounters.
Study: NCT06777225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercises
Description: This study is to examine the effects of breathing exercises on nausea, vomiting and anxiety levels in patients with gynecological cancer.~1 Exercise:~* Find a quiet, calm and comfortable place for yourself.~* Lie on your back in a comfortable place (flat surface, bed or couch) and bend your knees or sit in a comfortable place (chair or armchair).~* Close your eyes.~* Place your left hand on your belly and your right hand on your chest.~* Take a deep breath through your nose for 4 seconds.~* Feel your hand on your belly rise and your belly swell as you breathe in.~* Make sure your chest is not swollen.~* Hold your breath for 4 seconds. Breathe out in 4 seconds.~* Do this 10 times every day, morning and evening, 3 times.

Intervention type: OTHER
Group type: OTHER
Intervention: scale
Description: The patient received standard nursing care and the scale was applied after the intervention. The 21-question inventory developed by Dr. Aaron T. Beck was used. The reliability and validity of the Beck Depression Inventory (BDI), which is used to measure the severity of depression, was performed in our country by N. Hisli in 1989. (Cronbach's alpha value was calculated as 0.85). Each question takes a value between 0-3 points. When evaluating the results; 0-10 points are normal; 11-16 points are mild mood disorder; 17-20 points are borderline clinical depression; 21-30 points are moderate depression; 31-40 points are severe depression and over 40 points are very severe depression (Çiçekçe et al, 2023).
Study: NCT06148792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: oral treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafenoquine
Description: oral treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: oral treatment
Study: NCT04427397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sulcular Bristle Tip Technique (SBTT)
Description: Tooth brushing should begin on the distal of the most posterior tooth on one side of the mouth and proceed anteriorly and then posteriorly overlapping areas to the most distal surface of the most posterior tooth on the contra lateral side. The lingual is done in like fashion ending where the brushing began. The opposing arch is brushed in the same manner. When moving from one area to the next, disengage the brush bristles entirely off the teeth to allow them to straighten, and then reposition the brush in the next overlapping area. Do not to drag the bristle tips from one area to the next area. For the lingual of the anterior teeth, the narrow portion of the brush is used with the exact same technique as described above. For the lingual of the mandibular molars, the angulation of the toothbrush bristles to the tooth needs to be somewhat more perpendicular to the tooth than on the buccal to ensure that the bristle tips enter the gingival crevice.
Study: NCT05283642

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DCI
Description: Oral supplementation with D-chiro-inositol once daily
Study: NCT06101134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: relatlimab+nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: relatlimab+nivolumab+rHuPH20
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab+rHuPH20
Description: Specified dose on specified days
Study: NCT05707689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Entertainment gaming
Description: If needed, gaming schedule will be tailored based on the participants' individual needs (working, studying, family issues) as long as the total gaming hours will be achieved. Participants are encouraged not to play video games during the study period. Participants' gaming interventions will be monitored carefully and recorded after each gaming session in specific gaming diary.
Study: NCT06777225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scale
Description: The patient received standard nursing care and the scale was applied after the intervention. The 21-question inventory developed by Dr. Aaron T. Beck was used. The reliability and validity of the Beck Depression Inventory (BDI), which is used to measure the severity of depression, was performed in our country by N. Hisli in 1989. (Cronbach's alpha value was calculated as 0.85). Each question takes a value between 0-3 points. When evaluating the results; 0-10 points are normal; 11-16 points are mild mood disorder; 17-20 points are borderline clinical depression; 21-30 points are moderate depression; 31-40 points are severe depression and over 40 points are very severe depression (Çiçekçe et al, 2023).

Intervention type: OTHER
Group type: OTHER
Intervention: scala
Description: The scale was developed by Rhodes and McDaniel (1999), and its Turkish validity and reliability were carried out by Fatma Genç and Mehtap Tan. The scale, which evaluates the number and severity of nausea-vomiting-retching episodes in the last 24 hours, consists of eight items. The scale has three sub-dimensions: Symptom Experience, Symptom Formation, and Symptom Distress. The responses to the items on the five-point Likert-type scale are scored as 0 = minimum 22 distress level, 4 = maximum distress level. When evaluating the scores, items 1, 3, 6, and 7 are reversed. The highest score that can be obtained from the scale is 32, and higher scores mean that nausea-vomiting symptoms have increased in patients (Odabaşı et al, 2021).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scala
Description: The scale was developed by Rhodes and McDaniel (1999), and its Turkish validity and reliability were carried out by Fatma Genç and Mehtap Tan. The scale, which evaluates the number and severity of nausea-vomiting-retching episodes in the last 24 hours, consists of eight items. The scale has three sub-dimensions: Symptom Experience, Symptom Formation, and Symptom Distress. The responses to the items on the five-point Likert-type scale are scored as 0 = minimum 22 distress level, 4 = maximum distress level. When evaluating the scores, items 1, 3, 6, and 7 are reversed. The highest score that can be obtained from the scale is 32, and higher scores mean that nausea-vomiting symptoms have increased in patients (Odabaşı et al, 2021).
Study: NCT06775522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHP2205
Description: Test drug: YHP2205 Comparator: YHR2401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHP2205
Description: Test drug: YHP2205 Comparator: YHR2401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR2401
Description: Test drug: YHP2205 Comparator: YHR2401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR2401
Description: Test drug: YHP2205 Comparator: YHR2401
Study: NCT06776952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW5004 ; Chidamide placebo
Description: XNW5004 + Chidamide placebo
Study: NCT06296758

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional anesthesia
Description: ultrasound-guided suprainguinal fascia iliaca block with 40ml of ropivacaine local or ultrasound-guided femoral nerve block with 20ml of ropivacaine local anesthetic
Study: NCT06776952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW5004 placebo; Chidamide
Description: XNW5004 placebo + Chidamide
Study: NCT05651334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active repetitive Transcranial Magnetic Stimulation
Description: Active stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive Transcranial Magnetic Stimulation
Description: Sham stimulation
Study: NCT06776562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Education on activities of daily living will be provided. In addition, a program including muscle strengthening, neuromuscular control and flexibility exercises for lower extremity and trunk muscles will be performed. Exercise Program will be performed for 8 weeks, 2 sessions per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Education will be provided for activities of daily living. Individuals with dynamic knee valgus in the control group will not receive any intervention. Exercise program will be implemented after the end of the study.
Study: NCT06775457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sample collection
Description: Blood samples and fecal samples will be taken from patients during evaluation visits. Blood samples will be analyzed for the study of HERVs. While fecal samples will be analyzed for the characterization of gut microbiota.
Study: NCT06775886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myPACE+ algorithm
Description: myPACE+ algorithm with mono-fractional exponent